Category Health & IP

WHO Official On Antimicrobial Resistance: Poor Quality Medicines Entering At “Last Mile” To Patient

NEW YORK -- At a recent event on the margin of the United Nations General Assembly, a senior World Health Organization official gave an update on global efforts against substandard and falsified medicines in the context of the fight against antimicrobial resistance (AMR). And a key issue is that often after arriving safely in the capitals, something happens just before quality-assured medicines reach the patient, contributing to AMR.

WIPO, Pharma Join Forces To Set Up Database For Medicine Procurers

Today WIPO Director General Francis Gurry and Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), signed an agreement establishing the Patent Information Initiative for Medicines, or “Pat-INFORMED,” during the General Assemblies of the Member States of WIPO taking place this week. IFPMA worked with Intellectual Property Watch to prepare a Q&A with Mr Gurry and Mr Cueni about this new initiative.

Human Rights Go Hand In Hand With IP In Making Health Systems Work, UN Forum Hears

Innovation is vital for the development of medicines, but innovation without proper access to them is pointless, Roberto Azevêdo, Director-General of World Trade Organization has said. Several other agency heads spoke at the same event, where World Health Organization Director General Tedros Adhanom Ghebreyesus stressed the importance of universal health coverage.

Disparity In Access To Medicines Spurs “Humanitarian” Patent Licensing

“There are shameful access disparities around the world” to life-saving medicines, Harvard University Global Access in Action project Co-Director Quentin Palfrey said at a 26 September Center for Strategic and International Studies event in Washington, DC. And while some of the challenges to fuller access involve pricing, getting medicines to poorer countries or populations means overcoming the obstacles of insufficient research and development (R&D) incentives, access barriers and polarised politics, he said.

Use Competition Law For Wider Access To Cheap Medicines?

The topic of access to medicines has gained momentum in recent years as high prices of new medicines affect developing countries and developed countries. The role of competition legislation in preventing market abuses and monopoly situations has been pointed to as a possible lever to facilitate access to generic medicines and balance the potential negative effects of intellectual property protection.

Panel Advances Key Public Interest Issues In Gene Editing Technology

WASHINGTON, DC -- The still-emerging breakthrough CRISPR gene editing tool has the potential to transform the field and do enormous good for humankind. But let’s make sure we understand it better and ensure the public interest before launching into using it too widely. Meanwhile, companies and researchers are actively licensing the technology. That was a message of a set of panellists working close to CRISPR’s development, speaking at a recent event in Washington, DC.

Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence

A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. [Updated]